Sweden wants to link drug approval to environmental risk assessment
This article was originally published in SRA
Executive Summary
The Swedish Medical Products Agency is proposing that approval of human medicines in the European Union should require an environmental risk assessment of the production facilities where the products are manufactured and that marketing authorisation should be denied if any risk of negative environmental effects is found1.